PROCEPT BioRobotics (PRCT) Stock Analysis

What PROCEPT BioRobotics does

PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.

Key metrics

ETFs linked to PRCT

Broad-market and Healthcare sector ETFs an investor holding PROCEPT BioRobotics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PRCT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for PROCEPT BioRobotics?

PROCEPT BioRobotics trades under the ticker PRCT on NASDAQ.

Which exchange is PRCT listed on?

PRCT is listed on NASDAQ.

What sector does PROCEPT BioRobotics operate in?

PROCEPT BioRobotics is classified in the Healthcare sector (Medical - Devices industry).

How can PortView help analyze PRCT in a portfolio?

PortView shows PRCT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.